Familial cold urticaria Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Familial cold urticaria. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Familial cold urticaria receives a directional strategic score of 67/100, combining unmet need (81/100), competitive intensity (67/100, where higher means more competition) and market attractiveness (74/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

An autoinflammatory disease caused by mutations in the NLRP3 gene which encodes cryopyrin. It is characterized by short episodes of fever, rash, and arthralgia after exposure to cold or rapid decrease in temperature.

The reproducible entity is Patsnap disease ID 2605cf6a041f4dad9e159d08515cf352 with MeSH identifier D056587. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Meta-Analysis: Prevalence of Food Allergy and Food Allergens — China, 2000−2021 Meta-Analysis: Prevalence of Food Allergy and Food Allergens —China, 2000−2021

We selected 24 studies from 9,767 publications in this field, with data from 138,740 children and adults who met the inclusion criteria for the meta-analysis. Participants included infants, children, and adults of all ages. The combined prevalence of self-reported and hospital-diagnosed food allergy was 8% [95% confidence interval (CI): 6%–10%, P<0.05] (Figure 1A). The self-reported prevalence rate of food allergy was 12% (95% CI: 8%–15%), while that of hospital-diagnosed food allergy was 5% (95% CI: 4%–7%) (Figure 1B). In addition, the prevalence of food allergy in males and females were 9% (95% CI: 5%–13%) and 10% (95% CI: 5%–15%), respectively (Figure 1C). According to the scope of sample cities, we divided them into Northeast, North China, Central China, East China, South China, and Southwest for analysis. Owing to data limitations, no effective studies on Northeast, North, and Central China were observed (Figure 1D). The prevalence of food allergy in East China was 11% (95% CI: 6%–15%), higher than that in South China (8%; 95% CI: 4%–12%) and Southwest China (8%; 95% CI: 4%–11%). Furthermore, the prevalence of food allergy in children aged 4–17 years was the highest (10%; 95% CI: 7%–14%), followed by that in adults (7%; 95% CI: 2%–11%) and infants 6% (95% CI: 4%–8%) (Figure 1E). The results also showed that the prevalence of food allergy from 2009–2018 was 8% (95% CI: 6%–11%), higher than that in 1999–2008 (5%; 95% CI: 3%–7%) (Figure 1F), indicating that the prevalence of food allergy in China is on the rise. The proportion of different types of food allergies to the t

Review the epidemiology source

Epidemiology evidence 2: China CDC Weekly Reports (Vol. 7 No. 25 Jun. 20, 2025) Hemorrhagic Fever with Renal Syndrome and Diversity andDistribution of Hantaviruses — China, 2014–2023

RESULTS A total of 91,388 cases were reported from 31 PLADs in China between 2014 and 2023, with an average incidence rate of 0.65/100,000. The incidence rate fluctuated between 0.37 and 0.86 per 100,000 persons, peaking in 2018 (0.86/100,000) and reaching its lowest level in 2022 (0.37/100,000) (Figure 1A). Cases were reported across all age groups, with 72.21% aged 15–59 years, 2.57% ≤14 years, and 25.22% ≥60 years (Figure 1B). The proportion of cases ≥60 years increased from 20.26% in 2014 to 31.96% in 2023, while cases aged 15–59 years decreased from 77.77% to 64.28%, and cases ≤14 years slightly increased from 1.97% to 3.74%. Regional variations were evident in age distribution, with a high proportion of cases ≤14 years in Sichuan (12.86%) and Jiangxi (8.05%), and a high proportion of cases ≥60 years in Hubei (35.72%) and Jiangsu (31.07%) (Figure 1B). Regarding occupational distribution, farmers still constituted the majority of cases, though their proportion showed a downward trend to 64.59% in 2023, while the proportion of cases involving individuals performing household chores and unemployed persons increased to 11.88% in 2023. A total of 9 PLADs reported average annual incidence rates higher than the national average, including Shaanxi, Heilongjiang, Shandong, Liaoning, FIGURE 1. The reported cases of HFRS from 2014 to 2023 in China. (A) The number of national annually reported cases and incidence rate of HFRS; (B) The age distribution and proportion of age groups of the annually reported cases. Abbreviation: HFRS=hemorrhagic fever with renal syndrome.

Review the epidemiology source

Epidemiology evidence 3: Diagnosed Allergic Conditions in Adults: United States, 2021

g y p (p ) NOTES: Estimates are based on household interviews of a sample of the U.S.civilian noninstitutionalized population. Access data table for Figure 4 at: htt // d / h /d t /d t b i f /db460 t bl df#4 https://www.cdc.gov/nchs/data/databriefs/db460-tables.pdf#4. https://www.cdc.gov/nchs/data/databriefs/db460 tables.pdf#4. SOURCE: National Center for Health Statistics, National Health Interview Survey, 2021. NCHS Data Brief ■ No. 460 ■ January 2023 Summary In 2021, nearly one-third of adults aged 18 and over had a diagnosed seasonal allergy, eczema, or food allergy. Overall, seasonal allergy was the most common of the three allergies, with about one-quarter (25.7%) of adults having a diagnosed seasonal allergy, followed by eczema (7.3%) and food allergy (6.2%). For all three allergies, women were more likely than men to have a diagnosed allergy. The prevalence of diagnosed eczema and food allergy generally decreased with increasing age, while the prevalence of a diagnosed seasonal allergy was 24.7% in adults aged 18–44, 27.9% in adults aged 45–64, 26.4% in adults aged 65–74, and 21.7% in adults aged 75 and over. The prevalence of diagnosed seasonal allergies was highest in non-Hispanic White adults, whereas the prevalence of diagnosed eczema and food allergies was highest in non-Hispanic Black adults. Hispanic adults were less likely to have diagnosed seasonal allergies, eczema, and food allergies than non-Hispanic White and non-Hispanic Black adults.

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Familial cold urticaria, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Familial cold urticaria thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: IL-1β

Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908).

The mechanism anchor is IL1B. It is a pathway hypothesis, not a claim that every Familial cold urticaria patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 24 registered studies. Recent sampled records include:

• JPRN-UMIN000057626 — Effects of acupuncture points thermal stimulation leg warmers on Hie (cold sensation) in mature women; Complete: follow-up continuing; Not Applicable; sponsor Okamoto Industries, Inc.; enrollment 100.
• NCT06544018 — Circadian Rhythm Deregulation in Patients With CAPS (ICARUS); Recruiting; Not Applicable; sponsor Hospices Civils de Lyon; enrollment 30.
• NCT06460194 — Treatment of Frostbite Sequelae With Botulinum Toxin A; Withdrawn; Phase 2; sponsor University Hospital of North Norway; enrollment 0.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate IL1B relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Familial cold urticaria merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if IL1B modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Familial cold urticaria is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.